期刊文献+

甲磺酸多沙唑嗪片人体生物等效性试验研究 被引量:2

Determination of the Cefixime Concentrationin Human Plasma By HPLC-MS/MS
下载PDF
导出
摘要 目的:建立HPLC—MS/MS法测定人体血浆中甲磺酸多沙唑嗪浓度的方法。方法:以KromasilC_18(4.6mm×250mm,5μm)为色谱柱,流动相为乙腈:20mM乙酸胺(含0.3%甲酸)水溶液(55:45),流速为0.30mL·min-1,柱温为25℃,进样器温度为4℃,进样量为10μL,内标物为吡格列酮。结果:甲磺酸多沙唑嗪在血浆浓度0.3~100ng/mL范围内线性良好,定量下限为0.3ng/mL,日内RSD≤6.0%,日间RSD≤6.3%,回收率为96.58%~100.16%。结论:该法灵敏,检测结果准确,适用于甲磺酸多沙唑嗪片的人体生物等效性研究。 Objective: To establish a quantified analytical method for determination of Doxazosin Mesylate in human plasma by HPLC-MS/MS. Methods: The HPLC-MS/MS conditions adopted were column Kromasil C_18 (4. 6mm × 250mm, 5μm) ; a mobile phase of acetonitrile : 20mm ammonium acetate(containing 0.3% methanoic acid, 55 : 45);the flow rate was 0.30 mL · min-1 and the column temperature was 25℃, the injector temperature was 4℃ ;the injection volume was 10μL , Pioglitazone was used as inter- nal standard. Results:In human plasma, the standard curve was linear from 0.3 . 100 ng · mL-1 , The lower limit of quantification was 0.3ng · mL-1. The RSD of intra-day was less than 6.0% ,the RSD of inter-day was less than 6.3%, and the method recovery rate was 96.58 % - 100.16 %. Conclusion:The method simple, easy operation, sensitive and accurate, and suitable for Doxazosin Mesylate human bioequivalence research.
作者 韩颖 谢云
机构地区 湖北中医药大学
出处 《亚太传统医药》 2013年第10期15-17,共3页 Asia-Pacific Traditional Medicine
关键词 甲磺酸多沙唑嗪 HPLC—MS MS 人体生物等效性研究 Doxazosin Mesylate HPLC-MS/MS Bioequivalence Study
  • 相关文献

参考文献5

  • 1涂响安,王文卫,赵亮,梁辉,赵良运,邓立文,曾令友.前列安通联合甲磺酸多沙唑嗪控释片治疗Ⅲ型前列腺炎45例[J].广东医学,2008,29(10):1608-1610. 被引量:10
  • 2谢平,张毕奎,朱运贵,李焕德,陈本美,刘晓磊,冯胜.甲磺酸多沙唑嗪片的人体药动学研究[J].中国医院药学杂志,2006,26(8):940-942. 被引量:6
  • 3SRIPALAKIT P, NERMHOM P, MAPHANTA S, et aI. Bioequivalence evaluation of two formulation of doxazosin tablet in healthy thai male volunteers [J]. Drug Dev Ind Pharm, 2005,31(10) : 1035-1040.
  • 4MA N, LIU W, LI H, et al. LC-MS determination and rela- tive bioavailability of doxazosin mesylate tablets in healthy Chinese male volunteers[J]. J pharm Biomed Anal, 2007,43 (3) : 1049-1056.
  • 5国家食品药品监督管理局药品审评中心.化学药物制剂人体生物利用度和生物等效性研究技术指导原则[S].国家食品药品监督管理局[H]GCL2-1,2005.

二级参考文献13

  • 1卢竞前,曹晶茗.多沙唑嗪应用于心血管病的研究进展[J].现代中西医结合杂志,2005,14(9):1242-1244. 被引量:5
  • 2蒋克泉,朋立超,周任远,吴贵龙,杨美蓉.直线偏光近红外线经会阴部照射治疗慢性前列腺炎及其疼痛的疗效[J].中国临床医学,2006,13(2):322-323. 被引量:5
  • 3Sripalakit P, Nermhom P, Saraphanchotiwitthaya A. Improvement of doxazosin determination in human plasma using high-performance liquid chromatography with fluorescence detection[J]. J Chromatogr Sci,2005,43(2) :63-66.
  • 4Sripalakit P, Nermhom P, Maphanta S,et al. Bioequivalence evaluation of two formulations of doxazosin tablet in healthy thai male volunteers[J]. Drug Dev Ind Pharm, 2005, 31 (10):1035-40.
  • 5COLLINS M M, STAFFORD R S, O' LEARY M P, et al. How common is prostatitis? A national survey of physician visits[ J]. J Urol, 1998, 159(4): 1 224-1 228.
  • 6KRIEGER J N, EGAN K J, ROSS S O, et al. Chronic pelvic pains represent the most prominent urogenital symptoms of “chronic prostatitis” [J]. Urology, 1996, 48(5) : 715 -722.
  • 7KRIEGER J N, NYBERG L J R, NICKEL J C. NIH consensus definition and classification of prostatitis [ J ]. JAMA, 1999, 282 (3) : 236 - 237.
  • 8CHUNG M, VASHI V, PUENTE J, et al. Clinical pharmacokinetics of doxazosin in a controlled - release gastrointestinal therapetic system (GITS) formulation[ J]. Br J Pharmacol, 1999, 48 (5) : 678 - 687.
  • 9KIRBY R S. A randomized, double - blind crossover study of tamsulosin and controlled release doxazosin in patients with benign prostatic hyperplasia[ J1. BJU International, 21303, 91 ( 1 ) : 41 -44.
  • 10EVLIYAOGLU Y, BURGUT R. Lower urinary tract symptoms,pain and quality of life assessment in chronic non - bacterial prostatitis patients treated with alpha -blocking agent doxazosin ; versus placebo[J], lnt Urol Nephrol, 2002, 34(3) : 351 -356.

共引文献13

同被引文献10

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部